Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.41
-2.9%		$0.56
$0.38
▼
$15.00
$69.39M-0.152,843 shs123,668 shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.73
-1.0%		$0.67
$0.49
▼
$2.25
$68.57M3.48117,183 shs23,801 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.26
-64.9%		$0.83
$0.23
▼
$1.55
$40.88M1.62222,758 shs27.27 million shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.03
-1.0%		$1.12
$1.03
▼
$1.95
$64.40M1.24532,402 shs220,270 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.46%+5.06%-24.36%-50.21%+41,699,900.00%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-2.06%+17.92%+6.73%-18.35%-59.25%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-5.70%+2.34%-5.53%-33.54%-34.14%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-0.95%0.00%-7.14%-11.86%-37.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.41
-2.9%		$0.56
$0.38
▼
$15.00
$69.39M-0.152,843 shs123,668 shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$0.73
-1.0%		$0.67
$0.49
▼
$2.25
$68.57M3.48117,183 shs23,801 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.26
-64.9%		$0.83
$0.23
▼
$1.55
$40.88M1.62222,758 shs27.27 million shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.03
-1.0%		$1.12
$1.03
▼
$1.95
$64.40M1.24532,402 shs220,270 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+0.46%+5.06%-24.36%-50.21%+41,699,900.00%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-2.06%+17.92%+6.73%-18.35%-59.25%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-5.70%+2.34%-5.53%-33.54%-34.14%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-0.95%0.00%-7.14%-11.86%-37.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
2.33
Hold$6.00721.92% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.33
Hold$9.003,404.67% Upside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
1.75
Reduce$3.00191.26% Upside

Current Analyst Ratings Breakdown

Latest PDSB, CTOR, ALPS, and PLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/14/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/6/2026
ALPS
ALPS Group Inc Ordinary Share
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/30/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/16/2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
N/AN/A$0.18 per share2.27($3.10) per shareN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.54 per shareN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.18 per shareN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M40.37N/AN/A$2.95 per share0.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$980K$0.331.26N/AN/AN/AN/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$24.76M-$0.47N/AN/AN/AN/A-99.47%-42.16%8/18/2026 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%N/A

Latest PDSB, CTOR, ALPS, and PLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q3 2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.04N/AN/AN/A$5.83 millionN/A
8/12/2026Q2 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.13N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.3418-$0.36-$0.0182-$0.36N/AN/A
5/15/2026Q2 2026
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.01-$0.27-$0.26-$0.27$7.00 million$1.67 million
5/13/2026Q1 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.15-$0.13+$0.02-$0.13N/AN/A
5/11/2026Q1 2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.36-$0.32+$0.04-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.11
0.50
0.12
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.73
2.26
2.26
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
16.89
16.89

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
0.81%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
9.80%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8.40%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
N/A166.40 million165.05 millionN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A92.98 million83.87 millionN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2055.92 million51.23 millionOptionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.92 million56.51 millionOptionable

Recent News About These Companies

Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS
August 11 at 4:25 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pliant-therapeutics-nasdaqplrx-posts-earnings-results-misses-estimates-by-002-eps-2026-08-11/
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 11 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343151/0/en/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html
Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pliant-therapeutics-plrx-expected-to-release-quarterly-earnings-on-thursday-2026-07-30/
Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLC
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pliant-therapeutics-inc-plrx-stock-position-raised-by-adar1-capital-management-llc-2026-07-29/
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Reduce" by Brokerages
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pliant-therapeutics-inc-nasdaqplrx-given-consensus-rating-of-reduce-by-brokerages-2026-07-24/
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 7% - Here's Why
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pliant-therapeutics-nasdaqplrx-trading-down-7-heres-why-2026-07-20/
Pliant Therapeutics adds independent directors to strengthen R&D
July 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pliant-therapeutics-adds-independent-directors-to-strengthen-rd?utm_source=marketbeat.com&utm_medium=referral
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326187/0/en/pliant-therapeutics-names-flavia-borellini-ph-d-and-robert-iannone-m-d-m-s-c-e-to-board-of-directors.html
Pliant Therapeutics Shareholders Approve Directors and Executive Pay
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pliant-therapeutics-shareholders-approve-directors-and-executive-pay?utm_source=marketbeat.com&utm_medium=referral
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
May 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4908144-pliant-therapeutics-inc-plrx-presents-at-rbc-capital-markets-global-healthcare-conference
Pliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026
May 21, 2026  |  quiverquant.comQ
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299809/0/en/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting.html
Pliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | Benzinga
May 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PLRX/short-interest
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/pliant-therapeutics-provides-corporate-reports-200500848.html
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288804/0/en/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference.html
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors-1036086458
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284839/0/en/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors.html
Pliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026
April 18, 2026  |  quiverquant.comQ
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
April 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/18/3276583/0/en/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting.html
Pliant Therapeutics Launches New $50 Million ATM Program
March 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pliant-therapeutics-launches-new-50-million-atm-program?utm_source=marketbeat.com&utm_medium=referral
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/pliant-therapeutics-plrx-price-target-decreased-by-1795-to-272/ar-AA1ZwSIu

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
SK Hynix logo displayed on a lit panel inside a semiconductor manufacturing facility with robotic arms and equipment.
The SK Hynix IPO and 2027’s AI Memory Squeeze
By Jeffrey Neal Johnson | July 13, 2026
A semi-truck hauls a large cylindrical industrial component past police cars on a nighttime industrial roadway.
These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
By Nathan Reiff | July 28, 2026
Coastal oil refinery with storage tanks, a gas flare stack, and tankers anchored offshore at dusk.
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
By Jessica Mitacek | July 15, 2026

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.40 -0.01 (-2.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 -0.01 (-2.22%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$0.73 -0.01 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 0.00 (0.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$0.26 -0.47 (-64.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.27 +0.01 (+5.53%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.03 -0.01 (-0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$1.07 +0.04 (+3.88%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas